BOW MEDICAL PRACTICE
ITER CROSS, BOW, CREDITON
HF004
In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction who are currently treated with an ACE-I or ARB, the percentage of patients who are additionally currently treated with a beta- blocker licensed for heart failure for heart failure
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 2 | 3 | 66.7% | |
| HF 4 | 2011 | 4 | 5 | 80.0% | |
| HF 4 | 2012 | 7 | 8 | 87.5% | |
| HF 4 | 2013 | 10 | 10 | 100.0% | |
| HF004 | 2014 | 9 | 9 | 100.0% | |
| HF004 | 2015 | 9 | 9 | 100.0% | |
| HF004 | 2016 | 15 | 16 | 93.8% | |
| HF004 | 2017 | 15 | 17 | 88.2% | |
| HF004 | 2018 | 14 | 16 | 87.5% | |
| HF004 | 2019 | 11 | 15 | 73.3% | |
| HF004 | 2020 | 14 | 18 | 77.8% | |
| HF006 | 2021 | 18 | 21 | 85.7% | |
| HF006 | 2022 | 15 | 16 | 93.8% | |
| HF006 | 2023 | 20 | 21 | 95.2% |
